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Atherothrombosis, characterized by atherosclerotic plaque rupture and subsequent occlusive or subocclusive thrombus
formation is the primary cause of acute ischemic syndromes involving all vascular beds and accounts for more than
one-third of all deaths in the developed world. Platelet activation and aggregation constitute the most critical component
in the pathophysiology of atherothrombotic disease. Aspirin is currently the most commonly used antiplatelet agent and
one of the most frequently prescribed drugs, with as many as 30 million Americans on chronic aspirin regimens. Multiple
well-designed prospective randomized clinical trials have demonstrated aspirin’s efficacy in both primary and secondary
prevention of a wide variety of entities that the atherothrombotic disease spectrum encompasses, such as cerebrovascular,
coronary artery, and peripheral vascular disease. Despite its proven benefit, however, a growing body of evidence suggests
that up to 70% of aspirin-takers may still be at risk for atherothrombotic complications due to resistance. Patients with
laboratory-confirmed aspirin resistance seem to have an almost fourfold increase in their risk for acute thrombotic
episodes, which underlines the magnitude of the problem for the vascular specialist. In this article, we review the
physiology of platelet activation and the role of aspirin as an antiplatelet agent; the various laboratory assays used in
assessing aspirin effectiveness; and current data on aspirin resistance and its clinical implications in patients with
cardiovascular disease. We also review the studies that explore this phenomenon in patients with peripheral arterial disease
and discuss the optimal management options in aspirin-resistant individuals. Suggestions are advanced for the direction
of future trials evaluating aspirin resistance in patients with vascular disease. ( J Vasc Surg 2009;50:1500-10.)Atherothrombosis, characterized by atherosclerotic le-
sion disruption with associated thrombotic complications,
is the primary cause of acute ischemic syndromes involving
all vascular beds and accounts for up to 35% of all deaths in
the developed world.1 In a meta-analysis of 287 random-
ized trials involving more than 200,000 patients, the Anti-
thrombotic Trialists’ Collaboration has demonstrated a
22% reduction in morbidity and mortality from serious
ischemic cardiovascular episodes with aspirin therapy com-
pared to placebo.2 As a result, aspirin (acetylsalicylic acid
[ASA]) has become the most cost-effective and widely used
agent in the primary and secondary prevention of athero-
sclerotic disease, with an estimated 30 million Americans
on a chronic aspirin regimen. However, despite its wide
acceptance and utilization, aspirin’s antiplatelet effect is not
From the Department Surgery, Creighton University Medical Center,a and
the Division of Vascular Surgery, University of Nebraska Medical Center.b
Competition of interest: none.
Reprint requests: Thomas G. Lynch, MD, University of Nebraska Medical
Center, Department of Surgery, 983280 Nebraska Medical Center,
Omaha, NE 68198-3280 (e-mail: tlynch@unmc.edu).
The editors and reviewers of this article have no relevant financial relation-
ships to disclose per the JVS policy that requires reviewers to decline
review of any manuscript for which they may have a competition of
interest.
0741-5214/$36.00
Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.
doi:10.1016/j.jvs.2009.06.023
1500uniform and persistent platelet reactivity has been demon-
strated in up to 70% of patients on aspirin therapy3-42
(Table I), suggesting that up to 21 million Americans on
aspirin regimens may not enjoy its beneficial cardiovascular
effects. In this article, we review the currently available data
on aspirin resistance; its prevalence and etiology; the labo-
ratory assays used to assess aspirin effect; and the implica-
tions of aspirin resistance in the practice of vascular surgery.
ASPIRIN: THE HISTORY
ASA - more commonly known as aspirin - is one of the
oldest medications still in wide availability. Early accounts
indicate that Hippocrates used willow leaves, rich in ASA,
to relieve the aches associated with multiple illnesses in
ancient Greece.43 Reverend Edmund Stone was able to
isolate salicilin, the glycoside of salicylic acid and the active
ingredient of aspirin, from the bark of a willow tree in
England in 1763.44 This ‘newly’ discovered compound was
named for the Salix Alba, literally white willow. In the
1800s, various scientists were able to streamline the extrac-
tion of salicylic acid from willow bark, but it was not until
1897 that Felix Hoffmann, a German chemist working for
Friedrich Bayer, was able to develop a well-tolerated com-
pound and ASA was born.45 Bayer marketed aspirin in
1899 and dominated the flourishing market of pain reliev-
ers.43 Since then, aspirin has grown to become one of the
most commonly identified trade names around the globe
articip
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modern medical literature, the antithrombotic effects of
aspirin were first reported in the Mississippi Valley Medical
Journal in 1953.46 Since then, numerous studies have
confirmed aspirin’s antiplatelet effect, establishing its ther-
apeutic efficacy and validating its widespread use.
MECHANISM OF ACTION
Platelets in hemostasis. Upon injury of the blood
vessel intima, as it occurs after trauma or rupture of an
Table I. Prevalence of aspirin resistance as diagnosed by la
Clinical setting Investigator n 
CVD Grundmann et al3 53 P
CVD Alberts et al4 39 P
CVD Alberts et al4 87 P
CVD McCabe et al5 47 P
CVD Berrouschot et al6 240 L
CVD Helgason et al7 306 L
CVD Grotemeyer et al8 306 L
CVD Grotemeyer9 180 P
CABG Zimmermann et al10 20 L
CABG Yilmaz et al11 14 P
CABG Buchanan12 40 B
CABG Buchanan13 289 B
CABG Poston et al14 225 IA
PCI Chen et al15 151 R
PCI Zhang et al16 256 L
PCI Lev et al17 150 L
PCI Gurbel et al18 191 T
Stable CAD Macchi et al19 160 P
Stable CAD Christiaens et al20 50 P
Stable CAD Pamukcu et al21 62 P
Stable CAD Macchi et al22 72 P
Stable CAD Gum et al23 325 P
Stable CAD Gum et al23 325 L
Stable CAD Friend et al24 325 L
Stable CAD Tantry et al25 223 L
Stable CAD Lee et al26 468 R
MI Borna et al27 64 P
MI Andersen et al28 58 P
MI Andersen et al28 71 P
MI Hobikoglu et al29 204 P
MI Stejskal et al30 103 L
MI Faraday et al31 30 L
MI Schwartz et al32 190 L
MI Cotter et al33 61 T
CHF Sane et al34 88 P
CEA Payne et al35 50 L
Post-CEA Assadian et al36 86 P
PVD Ziegler et al37 52 P
PVD Mueller et al38 100 L
Risk factors Malinin et al39 141 L
Risk factors Malinin et al39 141 R
Risk factors Wang et al40 422 R
Healthy adults Marshall et al41 12 P
Various patients Hillarp et al42 122 IA
CVD, Cerebrovascular disease; CABG, coronary artery bypass grafting;
myocardial infarction;CHF, congestive heart failure;CEA, carotid endartere
light transmission aggregometry; PR, platelet reactivity; BT, bleeding time;
function assay; TXB, thromboxane B; CD62p, CD62p flow cytometry.
The aspirin dose, the platelet assay utilized, and the number of individuals p
aspirin takers may be resistant to the medication.atherosclerotic plaque, subendothelial collagen and vonWillebrand factor (vWF) are exposed to circulating blood
components. Platelets adhere to both collagen and vWF on
the injured endothelium through their glycoprotein Ia/IIa
and Ib/V/IX receptors, respectively,47 eliciting the release
of calcium. Calcium induces a conformational change in
the platelet glycoprotein IIb/IIIa (gp IIb/IIIa) receptors,
so they are able to bind circulating fibrinogen molecules.
Calcium also stimulates the release of -granules and dense
granules. P-Selectin, one of the proteins released from
-granules, mediates the adhesion of monocytes and neu-
tory assays in various clinical settings
Platelet assay ASA dose (mg) Prevalence
00 100 22.6%
00 81 56.0%
00 325 28.0%
00 75-300 46.8%
300 12.5%
325-1300 25.5%
325 25.0%
1500 33.0%
100 15.0%
00 80-325 7.1%
325 42.0%
325 54.0%
B2 levels, TEG, CD62p 325 21.8%
81-325 19.2%
100 26.2%
81-325 12.7%
81-325 23.6%
00 98 29.0%
00 75-300 20.0%
00 300 12.9%
00 160 29.2%
00 325 9.5%
325 5.5%
56 25.0%
325 0.4%
81-325 27.0%
00 75-325 31.3%
00 75 40.0%
00 160 35.0%
00 100-300 33.8%
100 70.1%
325 6.7%
81-325 0.5%
evels 100 14.7%
00 325 55.0%
150 56.0%
00 100 16.0%
00 100 9.6%
325 60.0%
325 0.7%
325 7.0%
81-325 23.4%
00, BT 2250 8.3%
75-160 0.8%
percutaneous coronary intervention; CAD, coronary artery disease; MI,
; PVD, peripheral vascular disease; PFA-100, platelet function analysis; LTA,
pedance aggregometry; TEG, thromboelastography; RPFA, rapid platelet
ating in each study are shown. As few as 0.4% or as many as 70% of chronicbora
FA-1
FA-1
FA-1
FA-1
TA
TA
TA
R
TA
FA-1
T
T
, TX
PFA
TA
TA
EG
FA-1
FA-1
FA-1
FA-1
FA-1
TA
TA
TA
PFA
FA-1
FA-1
FA-1
FA-1
TA
TA
TA
XB2 l
FA-1
TA
FA-1
FA-1
TA
TA
PFA
PFA
FA-1
PCI,
ctomy
IA, imtrophils to activated platelets.48 This function is integral to
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the perpetuation of thrombogenesis, and the overall hemo-
static process.48 Dense granules release adenosine diphos-
phate (ADP), which further perpetuates platelet activation
by binding to ADP-specific receptors (P2Y1) and promotes
the action of phospholipase A2 on membrane phospholipid
compounds to produce arachidonic acid (ARA).49 Arachi-
donic acid is subsequently converted into thromboxane A2
(TXA2) and prostaglandins (mainly G2 and H2) within
platelets, a conversion mediated by thromboxane synthase
and the cyclooxygenase (COX) isoenzymes 1 and 2, respec-
tively.50 TXA2 is the most important platelet activator and
functions by inducing expression of fibrinogen receptors
(gp IIb/IIIa) on the platelet membrane and by binding to
TXA2 receptors on the surface of other platelets triggering
their activation.49 It also plays a secondary, but equally
important role in hemostasis, as a potent vasoconstrictor.
Platelet activation also occurs with the attachment of other
freely circulating nascent compounds, such as ADP, fibrin-
ogen, thrombin, adrenalin, and prostaglandin I2, to corre-
sponding ligand-specific receptors49 (Fig).
Aspirin effect on platelet activation. Aspirin irrevers-
ibly inhibits COX-1 in platelets by acetylating its serine-529
residue, thereby blocking TXA2 and other eicosanoid pro-
duction from ARA. TXA2 is the most significant trigger for
platelet activation and because platelets lack a nucleus, and
therefore are deprived of proteinosynthetic ability, this
inhibition cannot be overcome by new COX-1 synthesis
and thus lasts for the platelet’s lifespan (7-10 days). Aspirin-
induced COX-1 inhibition is rapid, irreversible, and satu-
Fig. Mechanisms for platelet activation: substances in th
activators that exert their mechanism attaching to spe
antagonists appear in red.rable at low doses (dose-independent).49 After a single 325mg dose of ASA, platelet COX-1 activity is completely
inhibited and recovers by about 10% per day, due to nascent
platelet release in the circulation.49
Aspirin metabolism. Appreciable aspirin concentra-
tions are found in plasma in less than 30 minutes after
ingestion. After a single dose, a peak value is reached in
about 1 hour and then declines gradually, with a half-life of
about 2-3 hours at antiplatelet doses.51 This is a result of
hydrolysis in the liver (hepatic endoplasmic reticulum and
mitochondria), plasma (by freely circulating hydrolases),
and erythrocytes. As mentioned earlier, COX-1-dependent
TXA2 inhibition lasts throughout a platelet’s lifespan,
thereby aspirin effects are maintained with daily dosing
intervals. At the concentrations encountered clinically,
roughly 80% to 90% of the salicylate in plasma is bound to
albumin; the percentage that is protein-bound declines as
concentrations increase. Hypoproteinemia and a variety of
other compounds that compete with aspirin for plasma
protein binding sites (such as thyroxine, triiodothyronine,
phenytoin, sulfinpyrazone, bilirubin, uric acid, penicillins,
and other nonsteroidal anti-inflammatory drugs) as a con-
sequence, are associated with proportionately higher levels
of free salicylates in the bloodstream.51,52
ASPIRIN RESISTANCE: LABORATORY
EVALUATION
Aspirin resistance can either be identified on clinical
grounds or detected with laboratory tests that assess plate-
let activation. Clinical resistance refers to the drug’s inabil-
ity to prevent clinical atherothrombotic events in patients
of the figure correspond to the most common platelet
ed platelet surface receptors. Pathway-specific platelete top
cializtreated with ASA. However, the latter phenomenon should
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because not all reports of atherothrombotic events take into
account potential patient noncompliance. Laboratory aspi-
rin resistance, on the other hand, is defined as ASA failure to
inhibit platelet aggregation in a predictable, measurable
fashion.50,53
PLATELET ASSAYS
Numerous assays have been developed to measure
platelet reactivity and, hence, indirectly quantify aspirin’s
antiplatelet effect. However, when attempting to interpret
studies investigating laboratory-identified ASA resistance,
it should be taken into account that most of these assays
measure platelet aggregation that may not necessarily be
specific for TXA2-induced platelet reactivity. Therefore,
laboratory studies may indicate an individual is ASA-
resistant if platelets are aggregating from a trigger other
than TXA2, even though aspirin might be effectively inhib-
iting COX-1, its sole target. The studies that utilize ASA
metabolites are a notable exception.
Due to its simplicity, the most commonly utilized assay
is the Platelet Function Analyzer-100 (PFA-100; Dade-
Behring, Deerfield, Ill). However, Light Transmission Ag-
gregometry (LTA) (Accumetrics Inc, San Diego, Calif)
remains the “gold standard” for monitoring platelet func-
tion, despite being more demanding technically.
Bleeding time. Bleeding time (BT) provides an indi-
rect measure of the time needed for a platelet plug to form
when a puncture of standardized dimensions is made on the
skin and is the only platelet assay that can be performed in
vivo. BT is relatively independent of coagulation factor
disorders (it is normal in patients with hemophilia) and,
therefore, a fairly good gauge of platelet function. How-
ever, it assumes that capillary function is normal. Falsely-
elevated results can be seen in thrombocytopenic individu-
als, patients with disseminated intravascular coagulation,
vWF, and less frequently in coumadinized patients.
Thromboxane and aspirin metabolites. Stable me-
tabolites of TXA2, such as serum TXB2 or urinary 11-
dehydro-TXB2, have been used by many to evaluate aspirin
resistance.14,33 These tests do not directly measure platelet
reactivity and are not platelet-specific: TXA2 is also pro-
duced by monocytes, macrophages, endothelial cells, and
perhaps platelets through the action of COX-2 and, there-
fore, may lead to TXB2 production that occurs regardless of
platelet-derived TXA2 inhibition. For this reason, use of
TXA2 metabolites to assess aspirin resistance has been
mostly abandoned, and is only useful in monitoring com-
pliance. Similarly, aspirin metabolites have not been used to
assess resistance, due to significant interindividual variabil-
ity in salicylate metabolism.
Light transmission and impedance aggregometry.
LTA quantifies platelet activation in vitro using an aggre-
gometer that measures the optical density of platelet-rich
plasma (obtained with centrifugation) after platelet aggre-
gation is induced with the addition of an agonist, such as
ARA, thrombin, collagen, epinephrine, or ADP. Although
an indirect index, LTA is considered the “gold standard”for monitoring platelet function.50 Impedance aggregom-
etry (IA) is based on the same principle, but uses whole
blood and measures electric impedance instead of light
transmission. This technique is simpler and more practi-
cal than LTA because it does not require sample centrif-
ugation.50
PFA-100. The assay simulates the in vivo function of
platelets in primary hemostasis and can be regarded as an in
vitro bleeding time recorder.54 In this test (Dade-Behring),
a whole blood sample aspirated from a capillary is antico-
agulated with citrate and then run through a cartridge
coated with a platelet agonist (collagen/ADP or epineph-
rine). The cartridge has a hole of standardized dimensions
in its center. Irreversible platelet aggregation results in
formation of a stable platelet plug which closes the central
hole. The time required for blood flow cessation is ex-
pressed as closure time (higher values indicate aspirin non-
responsiveness) and provides a measure of platelet hemo-
static capacity.50
Rapid platelet function assay (RPFA). In this point-
of-care test, sampled capillary blood is run through a trans-
parent fibrinogen-coated cartridge that contains platelet
agonists, such as ARA, collagen, or epinephrine (Accumet-
rics Inc). As thrombus is formed on its surface, light trans-
mission through the cartridge changes, providing an indi-
rect measure of platelet activation.
Platelet reactivity (PR). The PR test measures plate-
let activation triggered by a standardized vascular injury.
Blood from a forearm vein is sampled in a standardized
fashion and then mixed with either EDTA-buffer or
EDTA-formaldehyde-buffer, respectively. While in the
EDTA-buffer, the activated platelets are dissolved while
they remain fixed in the EDTA-formaldehyde medium.
Centrifugation causes only unattached, nonactivated plate-
lets to remain in the supernatant and a platelet counter
determines the numbers in each supernatant. The measure-
ment is inversely proportional to the number of unattached
platelets.
Flow cytometric analysis. Flow cytometry has been
employed in recent studies to assess activation-dependent
changes in the surface expression of platelet receptors.
Serebruany et al55 studied platelet activation after stroke or
transient ischemic attack in patients on aspirin and those
who were aspirin-free. Using monoclonal antibodies,
they assessed expression of GPIIb/IIIa (CD41); GPIb
(CD42b); P-Selectin (CD62p); GPIIb/IIIa activity (PAC-1);
platelet/endothelial cell adhesion molecule, PECAM-1
(CD31); vitronectin receptor (CD51/CD61); lysosome-
associated membrane protein, LAMP-3 (CD63), LAMP-1
(CD107a); platelet endothelial tetraspan antigen, PETA-3
(CD151); CD40-ligand (CD154); thrombospondin (CD36),
and platelet-leukocyte aggregates (CD151, CD14).
Thrombospondin, GPIIb/IIIa, P-Selectin, CD40-ligand,
and platelet-monocyte aggregates were significantly lower
in the aspirin-treated group. Hezard et al56 found little
correlation between the PFA-100, platelet aggregometry,
and GPIIb/IIIa flow cytometry in patients receiving vari-
ous platelet regimens.
A-100
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and thereby provides an indirect assessment of ARA-
induced platelet aggregation.36 Flow cytometry for P-
Selectin expression seems promising as it is quite specific for
ASA use and yields results comparable to those obtained with
aggregometry,50,57 although at least one study demon-
strated that all patients receiving aspirin demonstrated ara-
chidonic acid induced expression of CD62p (P-Selectin),
using flow cytometry, whereas PFA-100 closure times in-
Table II. Laboratory assays used in the diagnosis of aspiri
Advantag
In vivo assays
Bleeding time * The only in vivo test
* Easy to perform, cheap
point-of-care
* Independent of coagu
In vitro assays
Thromboxane production assays
Serum TXB2 * Directly dependent on
therapeutic target, CO
* Indirect measure of co
Urinary 11-dehydro-TXB2 * As above
Thromboxane-dependent
platelet function assays
Light transmission
aggregometry
* Traditional ‘gold stand
* Correlates with clinica
* Requires significant sam
preparation
Impedance aggregometry * Minimal sample prepar
* Independent of platele
PFA-100 * Simple, rapid, inexpen
* Sensitive
* Available at point of ca
* Semi-automated
* Correlates with LTA
Ultegra (RPFA) * As above
Platelet reactivity * Simple, standardized
Activation-dependent changes in
platelet surface
P-Selectin (CD62p) flow-
cytometric analysis
* Correlates well with LT
* Low sample volume
* Whole blood assay
* Promising method
Platelet surface activated GP
IIb/IIIa
* Low sample volume
* Whole blood assay
Leukocyte-platelet aggregates
flow cytometry
* As above
ASA, Acetylsalicylic acid; TXB, thromboxane B; COX, cyclooxygenase; PF
transmission aggregometry; CD62p, CD62p flow cytometry.dicated 16% of patients taking aspirin showed no effect ofaspirin.36 The general characteristics of the assays currently
in use are summarized in Table II.
MECHANISMS FOR ASPIRIN RESISTANCE
The concept of therapeutic resistance emerged with the
clinical observation that chronic aspirin-takers are not in-
variably protected from acute cardiovascular events, even
though such an expectation would be overly optimistic,
given that only a 22% of aspirin-takers had demonstrated a
istance
Limitations
ilable at
disorders
* Not ASA specific
* Dependent on von Willebrand, platelet count,
anticoagulant use
* Poor reproducibility
* Poor correlation with other platelet function
assays
in’s
nce
* Not platelet-specific
* Operator-dependent
* Uncertain sensitivity, reproducibility
* Not widely evaluated
ts
* Not ASA-specific
* Limited availability
* Operator dependent
* Expensive and labor intensive
* Not standardized
* Depends on age, gender, race, diet, hematocrit
required
nt
* As above
* Not ASA specific
* Depends on von Willebrand factor and
hematocrit
* Not ASA specific
* Depends on von Willebrand factor and
hematocrit
* Less sensitive than PFA-100
* Not ASA specific
* Limited testing
* Uncertain sensitivity
* Not widely used nor thoroughly validated
* Uncertain sensitivity
* Expensive sample preparation
* Experience in flow cytometry required
* As above
* Poor correlation with PFA-100
* As per P-Selectin analysis
, platelet function analysis; RPFA, rapid platelet function assay; LTA, lightn res
es
, ava
lation
aspir
X-1
mplia
ard’
l even
ple
ation
t cou
sive
re
Atherapeutic advantage, as evidenced in the Antithrombotic
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platelet function has also been demonstrated in aspirin-
treated patients in multiple clinical settings including
healthy individuals,41 with risk factors,39,40 and patients
with coronary,10-33 peripheral vascular37,38 or cerebrovas-
cular disease.3-6 Unfortunately, due to lack of a consensus
definition and universally accepted diagnostic criteria, the
term aspirin resistance has been used in miscellaneous
clinical studies with diverse patient populations, different
aspirin regimens, and different assays for assessment of the
effect. This has resulted in reports of aspirin resistance
ranging from 0.4%25 to as high as 70%,30 further confusing
our understanding of this phenomenon.
Noncompliance. With up to 40% of cardiovascular
patients possibly being nonadherent with their regimens,
one obvious explanation for aspirin treatment failure is
noncompliance.32,33,58 Confirmed nonadherent patients
are significantly more likely to experience recurrent acute
cardiovascular episodes when compared to their biologically-
resistant counterparts.33 Unfortunately, there is no wid-
ely accepted gold standard for the assessment of compli-
ance. Continuous intake observation is not feasible on an
outpatient basis, verbal confirmation of aspirin intake by
patients is not always reliable, pill counts can be misleading
when medications are being discarded instead of ingested;
video surveillance in an in-patient setting can be burdened
with behavioral modification on the patient’s behalf when
they know they are being observed (Pygmalion effect); and
finally salicylate level measurement, although objective, can
be deceptive due to aspirin’s short half-life (about 30
minutes) and would fail to identify individuals who only
take their medications in anticipation of a doctor’s appoint-
ment (“white coat compliance”).59 Considering the rela-
tively high prevalence of noncompliance, many authors
have suggested that it is the predominant cause of resis-
tance.32,33,36,58,60-63
TXA2 independent platelet activation pathways. It
is well recognized that platelets can be activated indepen-
dently of TXA2 synthesis
64-66 and cannot, therefore, be
inhibited by ASA. This can occur via platelet membrane
receptors for ADP (P2Y1), thrombin and epinephrine, and
glycoprotein receptors for collagen (Ia/IIa), vWF (Ib/V/
IX), and fibrinogen (GP IIb/IIIa), as stated earlier.49 In
fact, it has been shown that the in vitro response of platelets
to ADP22 and collagen67 is much more pronounced in
aspirin-resistant individuals; and in vivo platelet activation
at the site of vascular injury in coronary artery disease seems
to be induced mainly through ADP-mediated pathways.68
Hereditary polymorphisms in the platelet membrane colla-
gen,69 ADP (P2Y1),19 fibrinogen and vWF (GP IIIa)70-73
receptors have also been shown to alter platelet reactivity,
significantly blunting the aspirin effect. In the case of the
GP IIIa receptor, certain alleles have been associated with a
significantly higher incidence of ischemic heart disease and
acute coronary events70,71,74,75 and could function as im-
portant predictors for sudden cardiac death.76
Alternative routes of TXA2 production. On a mo-
lecular level, ASA does not inhibit TXA2 synthesis, that canalso be generated by COX-2 in monocytes, macro-
phages,64,77 megakaryocytes, and a subpopulation of im-
mature platelets that carry this COX isoenzyme,78-80 This is
especially true when the numbers of these inflammatory
cells are increased (after atherothrombotic events or em-
bolic phenomena that cause cellular death, such as after a
myocardial infarction or an acute ischemic stroke),10 and in
high platelet turnover states (such as recent surgery, infec-
tion, and active atherosclerosis).80 COX-1 gene mutations
that decrease its affinity to aspirin have also been identi-
fied.42,81 Finally, individuals with regenerating or inducible
COX-1 in their megakaryocytes can demonstrate propor-
tionally greater platelet activation with prolonged aspirin
intake (tachyphylaxis).82
Inadequate dosing. Various randomized controlled
trials have demonstrated that daily, low-dose aspirin ther-
apy can suppress COX-1,83-86 corroborating the finding
that 325 mg of aspirin may not offer additional COX
inhibition compared to 81 mg, as this process is rapid,
irreversible, and saturable at low doses (dose-independent),
as stated earlier.49 Even though an across-the-board con-
sensus on the ideal aspirin dosage for primary and second-
ary prevention of atherothrombotic events seems to be
lacking,87,88 higher doses seem to be more effective in
clinical trials that use laboratory endpoints to measure
aspirin resistance.7,19,26,28,89-96 However, these findings
were not confirmed in studies with clinical outcome end-
points97 and meta-analyses of studies assessing the clinical
significance of laboratory-identified ASA resistance have
failed to demonstrate a similar dose-dependent effect.98
Variability in aspirin pharmacodynamics and phar-
macokinetics (absorption, bioavailability, metabolism,
and excretion). Absorption of orally ingested salicylates
occurs rapidly by passive diffusion across the gastric and
proximal small bowel mucosa and is influenced by gastric
pH. Rise in the pH enhances absorption mainly because it
accelerates dissolution of the tablets. Acid-lowering medi-
cations, therefore, accelerate absorption whereas presence
of food delays it.51 Although still in the bowel, a small
proportion of ingested salicylates can be inactivated by
esterases present in the intestinal brush border. Once in the
bloodstream, ASA is broken down by the liver, red blood
cells, and freely circulating plasma hydrolases.99-101 Inter-
individual variability in expression of the enzymes partici-
pating in aspirin metabolism may be partially responsible
for failure of aspirin to inactivate platelets. Furthermore,
once in the bloodstream, ASA competes with a variety of
other medications (such as thyroxine, triiodothyronine,
phenytoin, sulfinpyrazone, penicillins, and other NSAIDs)
and compounds (bilirubin, uric acid) for protein binding
sites. Presence of these medications lead to higher free
plasma salicylate levels, which may transiently increase its
antiplatelet effect, but will eventually render it more sus-
ceptible to the innate hydrolytic mechanisms. Finally,
changes in urinary pH can affect the rate of salicylate
elimination, with more alkaline urine eliminating aspirin
derivatives faster.51
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rect link between smoking and aspirin resistance are cur-
rently lacking, it seems that smokers are more likely to be
found resistant by PFA-100 analysis compared with their
nonsmoking counterparts (33.3% vs 12.5%; P  .05).22
This finding seems to be a result of the known procoagu-
lant properties that chronic smoking has, even despite
aspirin use.102
Duration of regimen. Although adequate platelet in-
hibition may be achieved in the first month of aspirin
treatment,9,85,100 loss of the therapeutic advantage has
been confirmed in individuals on long-term treatment,
particularly on regimens greater than 500 days in dura-
tion.7,23,82 This effect, that is demonstrated with labora-
tory assays, coincides with an increase of adverse cardiovas-
cular outcomes in aspirin users.103,104 Even though the
mechanism of this phenomenon is not well understood,
late tachyphylaxis, progression of atherosclerosis, inducible
COX-1, and perhaps most importantly, decreasing adher-
ence have all been postulated as plausible etiology.82
Lack of consensus on aspirin resistance definition.
The lack of a universally accepted, standardized laboratory
definition of aspirin resistance has led to a wide variation in
the reported prevalence. This is possibly a reflection of the
tests utilized (Table I), different agonists or even different
reference ranges used within the same method, and finally
the dissimilar patient population assessed in each study.
The prevalence of aspirin resistance ranges between 1% to
56% when the PFA-100 test is used, and between 7% to
27% when the RPFA assay is utilized. With LTA, however,
the reported prevalence seems to be wider, from 0.4% to
70%. Depending on what test is used, it is possible that as
few as 120,000, or as many as 21 million, Americans who
are on chronic aspirin therapy could be ASA-resistant and
therefore susceptible to acute atherothrombotic episodes.
Based on the published data to date, and irrespective of
the laboratory test used, it seems that the antiplatelet effects
of aspirin seem to be variable among individuals105 and
probably have a continuous, broad distribution, which not
only varies among individuals, but also in the same person
with time.50 This might help explain, to some extent, the
wide variation in the prevalence of aspirin resistance among
different studies with similar patient populations. Even
though a categoric definition of laboratory aspirin resis-
tance seems to carry a significant predictive risk for adverse
clinical events, it would be safe to infer that when seen as a
continuous variable, different levels of resistance can carry a
varying relationship with clinical outcomes.
CLINICAL IMPLICATIONS
Today, one of the most important questions clinicians
are called upon to answer is the extent to which laboratory
resistance to aspirin signifies clinical aspirin failure? Two
recent meta-analyses pooled data from a body of literature
that attempted to establish an association between labora-
tory aspirin resistance and risk of developing a subsequent
acute atherothrombotic event. In the first study, Krasopou-
los et al106 assessed the rate of cardiovascular events in 2930patients with cardiovascular disease on ASA therapy for
secondary prevention. Twenty-eight percent of all partici-
pating patients were found to be resistant by a variety of
laboratory assays. Out of the 20 studies pooled in this
meta-analysis, compliance was ensured or adjusted for in
17. Aspirin resistance was more prevalent among men and
patients with renal impairment (P  .001 and P  .03,
respectively). Aspirin-resistant patients, diagnosed in the
laboratory and irrespective of underlying condition or
symptomatology, were at greater risk for death, acute cor-
onary syndromes, new cerebrovascular episodes, or failure
of vascular intervention (39% vs 16%; odds ratio 3.85; 95%
confidence interval [CI] 3.08-4.80; P  .001). Unfortu-
nately, not only did aspirin resistance have an adverse
effect on prognosis, but this elevated risk was not atten-
uated by adjunct antiplatelet therapies, such as clopi-
dogrel or tirofiban.106
Similarly, Snoep et al98 pooled data from 16 studies
(n  2296) that assessed the odds ratio of developing a
recurrent acute cardiovascular episode despite aspirin use
for secondary prevention. Three of the included studies
were adjusted for aspirin noncompliance. In this selected-
patient group, 27% were found to be resistant by a variety of
laboratory assays. The pooled odds ratio for adverse clinical
events in aspirin-resistant patients without any adjunctive
interventional treatment, as measured by various laboratory
methods, was 4.37 (95% CI 2.19-8.73; P  .001). When
studies involving patients who had undergone interven-
tional procedures after a primary cardiovascular event were
included, the resulting odds ratio was 3.78 (95% CI 2.34-
6.11; P  .001), in agreement with the findings of Kraso-
poulos et al.106 When patients were stratified by aspirin
dose (100 mg/day; 101-299 mg/day; 300 mg/day),
no differences were found among the various dosage
groups. Both meta-analyses assumed laboratory aspirin re-
sistance to be a categoric variable (present vs not present).
ASPIRIN RESISTANCE IN VASCULAR
SURGERY
The majority of available studies on aspirin resistance
predominately involve patients with a history of stroke and
coronary artery disease, or even healthy individuals; the
phenomenon has not been thoroughly explored in the
vascular literature.107 Assadian et al36 reported aspirin non-
responsiveness to be 16%, as measured by PFA-100 analysis
with epinephrine as a catalyst, in 86 individuals who had
recently undergone CEA and were on 100 mg of aspirin
daily. However, when the same individuals were assessed
with flow cytometry for P-Selectin expression on platelets,
all patients were found to be ASA responsive.36 An inter-
esting demonstration of transient aspirin resistance despite
chronic aspirin intake has also been demonstrated in early
postoperative vascular surgery patients. Payne et al35 found
that 28 out of 50 patients undergoing CEA (who had
previously been on 150 mg of aspirin daily for at least 2
weeks) had significantly elevated platelet reactivity intraop-
eratively. This phenomenon, that was identified using light
aggregometry with ARA as an agonist, was short-lived and
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 6 Kasotakis et al 1507reversed spontaneously early in the postoperative period.
Similarly, peripheral vascular patients undergoing lower
extremity angioplasty had a significantly higher platelet
reactivity to ARA at the end of the procedure, compared to
preoperatively, as reported by Webster et al,108 but this
trend also self-reversed within 4 hours postoperatively.
Similar transient variations have been reported in the early
postprocedure periods after CABG.10 The increased plate-
let aggregation could not be attributed to the transient
intraoperative increases of ADP, thrombin, and epineph-
rine due to surgical stress, because in vitro addition of
inhibitors (apyrase, hirudin, and yohimbine correspond-
ingly) failed to significantly reduce platelet response to
ARA.35 Even though the clinical significance of this phe-
nomenon in the long term is uncertain, it could explain why
patients undergoing cardiovascular surgical procedures re-
main at risk for perioperative stroke and myocardial infarc-
tion.35 It also corroborates the notion that aspirin resis-
tance represents an ever-changing continuum that varies
from time to time even within the same individual.
Regarding the clinical relevance of aspirin resistance in
patients with peripheral arterial disease, Mueller et al38
followed a group of 100 claudicants on 100 mg of aspirin
daily for 18 months after undergoing elective percutaneous
angioplasty. The authors demonstrated that 60% of this
population demonstrated aspirin resistance by whole blood
aggregometry (using collagen, ADP, and ARA as agonists).
Eight of the 60 patients with ASA-resistance had reocclu-
sions at the site of angioplasty, although none of the
remaining 40 patients with normal ASA response (inhibited
platelet function) had an adverse event (P  .0093). Con-
tradicting these findings, Ziegler et al37 assessed platelet
inhibition using PFA-100 (ADP was the agonist utilized) in
98 patients with documented peripheral arterial disease on
100 mg of aspirin (n 52), 75 mg of clopidogrel (n 34)
or both (n  12) 1 year after elective lower extremity
angioplasty. Even though ASA-resistance was estimated at
9.6% (9/52), it did not correlate with a higher re-stenosis
or reocclusion rate at the angioplasty sites. Contrary, clopi-
dogrel nonresponders had a higher incidence of clinical
angioplasty failure compared to responders. However,
compliance was again not accounted for, patient selection
was not randomized, and the small number of participants
and short follow-up in this study may account for its lack of
power.
MANAGEMENT OF ASPIRIN-RESISTANT
INDIVIDUALS
The routine laboratory evaluation of platelet reactivity
is not cost-effective or justifiable in all individuals on
chronic aspirin regimens.60,109 If, however, clinical events
occur while on aspirin, compliance should be assessed and
optimized, polypharmacy checked, smoking cessation en-
couraged, and consideration be given to whether more
antiplatelet agents can be added or substitute aspirin. Such
agents inhibit upstream pathways of platelet activation
(such as ADP receptor antagonists [thienopyridines: clopi-
dogrel/Plavix, ticlopidine/Ticlid]), or phoshpodiesteraseinhibitors (dipyridamole/Persantine), or the final common
downstream pathway of platelet aggregation (such as GP
IIb/IIIa receptor inhibitors [eptifibatide/Integrillin, tiro-
fiban/Aggrastat, and abcimixab/Reopro]). Even though
evidence of the efficacy of such an approach is currently
conflicting and under debate,97,110-114 it is these individu-
als that would most benefit from routine, frequent moni-
toring of platelet activity.
CONCLUSIONS - FUTURE DIRECTIONS
Even though laboratory-diagnosed ASA-nonresponsiveness
confers a higher risk for acute thromboembolic sequelae to
nonresponders, it seems to represent a continuous variable,
affecting different individuals to an unpredictable extent.
Routine laboratory monitoring of platelet function in all
chronic aspirin-takers is not cost-effective, but should be
undertaken in all individuals with clinical aspirin failure,
after compliance is confirmed. For the individuals who are
identified as aspirin-resistant, the importance of compliance
must be stressed and smoking cessation encouraged; med-
ications that inhibit aspirin’s effectiveness should be
avoided (ie, NSAIDs), and the addition of other antiplate-
let drugs should be entertained.
Although consensus on a clear definition of, and labo-
ratory criteria for, aspirin resistance needs to be established,
incorporating standardized and reproducible assays, cur-
rent data from other cardiovascular subspecialties should
provide a springboard to stimulate research in the popula-
tion of patients with peripheral vascular disease. Interest in
this area among vascular surgeons should be significant,
given the number of vascular patients on aspirin mono-
therapy for primary or secondary prevention of acute
atherothrombotic episodes, or postrevascularization proce-
dures.
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